Amicus Therapeutics, Inc.

LSE:0HF9 Stock Report

Market Cap: US$2.8b

Amicus Therapeutics Valuation

Is 0HF9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HF9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$53.62
Fair Value
82.7% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: 0HF9 ($9.25) is trading below our estimate of fair value ($53.62)

Significantly Below Fair Value: 0HF9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HF9?

Key metric: As 0HF9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0HF9. This is calculated by dividing 0HF9's market cap by their current revenue.
What is 0HF9's PS Ratio?
PS Ratio5.7x
SalesUS$493.67m
Market CapUS$2.80b

Price to Sales Ratio vs Peers

How does 0HF9's PS Ratio compare to its peers?

The above table shows the PS ratio for 0HF9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.8x
GNS Genus
1.5x3.7%UK£984.0m
OXB Oxford Biomedica
4.4x21.2%UK£432.2m
BVXP Bioventix
12.7xn/aUK£172.2m
AVCT Avacta Group
8.6x0.4%UK£193.9m
0HF9 Amicus Therapeutics
5.7x18.6%US$2.8b

Price-To-Sales vs Peers: 0HF9 is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (6.8x).

Price to Sales Ratio vs Industry

How does 0HF9's PS Ratio compare vs other companies in the GB Biotechs Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.5x3.7%US$1.22b
TRX Tissue Regenix Group
1.6x15.1%US$51.53m
0HMP Bellerophon Therapeutics
0.09xn/aUS$489.31k
No more companies available in this PS range
0HF9 5.7xIndustry Avg. 8.1xNo. of Companies6PS01224364860+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0HF9 is good value based on its Price-To-Sales Ratio (5.7x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0HF9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HF9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.7x
Fair PS Ratio6.1x

Price-To-Sales vs Fair Ratio: 0HF9 is good value based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HF9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.25
US$17.33
+87.4%
16.0%US$21.00US$12.00n/a12
Jan ’26US$9.42
US$17.33
+84.0%
16.0%US$21.00US$12.00n/a12
Dec ’25US$9.98
US$17.75
+77.9%
12.8%US$21.00US$14.00n/a12
Nov ’25US$11.35
US$17.33
+52.7%
13.2%US$20.00US$13.00n/a12
Oct ’25US$10.58
US$17.25
+63.1%
14.8%US$20.00US$13.00n/a12
Sep ’25US$11.45
US$17.18
+50.1%
15.5%US$20.00US$13.00n/a11
Aug ’25US$10.20
US$17.36
+70.3%
15.8%US$21.00US$13.00n/a11
Jul ’25US$9.82
US$17.36
+76.8%
15.8%US$21.00US$13.00n/a11
Jun ’25US$9.85
US$17.36
+76.3%
15.8%US$21.00US$13.00n/a11
May ’25US$10.04
US$18.78
+87.1%
12.2%US$22.00US$14.00n/a9
Apr ’25US$11.71
US$19.00
+62.3%
9.9%US$22.00US$16.00n/a9
Mar ’25US$13.43
US$19.22
+43.1%
10.3%US$22.00US$16.00n/a9
Feb ’25US$12.74
US$19.56
+53.5%
8.4%US$22.00US$16.00n/a9
Jan ’25US$14.25
US$19.33
+35.7%
9.1%US$21.00US$15.00US$9.429
Dec ’24US$11.14
US$18.10
+62.5%
16.1%US$21.00US$12.00US$9.9810
Nov ’24US$11.06
US$17.50
+58.2%
16.6%US$21.00US$12.00US$11.3510
Oct ’24US$12.13
US$17.60
+45.1%
15.9%US$21.00US$12.00US$10.5810
Sep ’24US$12.99
US$16.40
+26.3%
15.0%US$20.00US$12.00US$11.4510
Aug ’24US$13.40
US$15.90
+18.7%
14.7%US$20.00US$12.00US$10.2010
Jul ’24US$12.56
US$15.80
+25.8%
14.4%US$20.00US$12.00US$9.8210
Jun ’24US$11.10
US$15.80
+42.3%
14.4%US$20.00US$12.00US$9.8510
May ’24US$11.65
US$15.70
+34.8%
15.6%US$20.00US$11.00US$10.0410
Apr ’24US$10.81
US$15.82
+46.3%
15.0%US$20.00US$11.00US$11.7111
Mar ’24US$13.63
US$15.45
+13.4%
14.7%US$20.00US$11.00US$13.4311
Feb ’24US$13.01
US$15.36
+18.1%
16.0%US$20.00US$10.00US$12.7411
Jan ’24US$12.06
US$14.82
+22.9%
16.7%US$20.00US$10.00US$14.2511
Analyst Price Target
Consensus Narrative from 12 Analysts
US$17.13
Fair Value
46.0% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 10:37
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicus Therapeutics, Inc. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Michael UlzBaird
Yun ZhongBerenberg